Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

BUY
$23.5 - $35.38 $4 Million - $6.01 Million
170,000 New
170,000 $5.95 Million
Q3 2021

Nov 15, 2021

SELL
$21.26 - $38.85 $14.4 Million - $26.2 Million
-675,670 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$12.56 - $29.69 $13.2 Million - $31.3 Million
-1,052,920 Reduced 60.91%
675,670 $17.3 Million
Q1 2021

May 17, 2021

SELL
$12.37 - $17.74 $480,574 - $689,198
-38,850 Reduced 2.2%
1,728,590 $23.7 Million
Q4 2020

Feb 16, 2021

BUY
$9.82 - $18.27 $17.4 Million - $32.3 Million
1,767,440 New
1,767,440 $29.3 Million

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Ally Bridge Group (Ny) LLC Portfolio

Follow Ally Bridge Group (Ny) LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ally Bridge Group (Ny) LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ally Bridge Group (Ny) LLC with notifications on news.